Latest

2 stories

Hide weekly roundups

Today

Quarterly updateIonis Pharmaceuticals olezarsen Research Alliance Corp IIIUpdated

Ionis cuts Tryngolza 2026 sales guidance, highlights Zanvastro launch and new Phase 3 wins

The company lowered Tryngolza product sales guidance to about $50 million while reporting positive Phase 3 results for sefaxersen and ulefnersen and a first Alexander disease launch.

SEC filing (2)

Wednesday, October 28

Quarterly updateAmarin Corp Plc\Uk

Amarin posts first profitable quarter in two years as VAZKEPA growth accelerates in Europe

Amarin reported Q3 2026 net income of $0.2 million as Recordati-driven European demand for VAZKEPA rose 68% and an investigator-led Phase 3 trial pointed to a possible new use for the drug in colorectal cancer.

SEC filing